Xenon Pharmaceuticals Stock | Price, Analyst Rating & Outlook for 2026

Xenon Pharmaceutical...

NasdaqGM:XENE

$ 44,33

$-0,51 (-1,14%)

44,33 $

$-0,51 (-1,14%)

End-of-day quote: 12/30/2025

Xenon Pharmaceuticals Stock Value

The analyst rating for NasdaqGM:XENE is currently Buy.

Buy

Xenon Pharmaceuticals Company Info

EPS Growth 5Y

-14,34%

Market Cap

$3,43 B

Long-Term Debt

$0,01 B

Short Interest

9,04%

Annual earnings

02/27/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1996

Industry

Health Care

Country

Canada

ISIN Number

CA98420N1050

Website

http://www.xenon-pharma.com

Analyst Price Target

$55,00

24.07%

Last Update: 12/31/2025

Analysts: 19

Highest Price Target $65,00

Average Price Target $55,00

Lowest Price Target $44,00

In the last five quarters, Xenon Pharmaceuticals’s Price Target has fallen from $54,61 to $51,46 - a -5,77% decrease. Fourteen analysts predict that Xenon Pharmaceuticals’s share price will increase in the coming year, reaching $55,00. This would represent an increase of 24,07%.

Top growth stocks in the health care sector (5Y.)

What does Xenon Pharmaceuticals do?

Xenon Pharmaceuticals Inc. operates as a neuroscience-focused biopharmaceutical company. The company is committed to improving the lives of people living with neurological and psychiatric disorders. The company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. In addition to its proprietary product candidates, the company has partnered programs with academic and industry collaborators, including Neurocrine Biosciences, Inc., or...

Strategy

The key components of the company’s strategy include leveraging its discovery capabilities – which were founded upon its understanding of the genetics of channelopathies combined with proprietary biology and medicinal chemistry assets and know-how – to identify product candidates for development, drug targets and/or new indications for its existing product candidates; advancing selected proprietary product candidates through clinical development; selectively establishing collaborations that allow it to potentially expand its internal capabilities and/or address broader commercial opportunities than may be possible independently; identifying opportunities to further expand its pipeline though indication expansion, acquisition, or in-licensing of external product candidates; and commercializing product candidates alone or in collaboration with others.

Product Candidates

XEN1101

XEN1101 is a novel, potent Kv7 potassium channel opener being developed for the treatment of epilepsy, major depressive disorder, or MDD, and potentially other neurological disorders.

XEN1101 for Epilepsy (Focal Onset Seizures)

The company’s XEN1101 Phase 3 epilepsy program includes two identical Phase 3 clinical trials, called X-TOLE2 and X-TOLE3 that are designed closely after the Phase 2b X-TOLE clinical trial. These multicenter, randomized, double-blind, placebo-controlled trials are evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of XEN1101 administered with food as adjunctive treatment in approximately 360 patients per study with focal onset seizures, or FOS. The primary efficacy endpoint is the median percent change, or MPC, in monthly seizure frequency from baseline through the double-blind period, or DBP, of XEN1101 compared to placebo. Xenon anticipates patient enrollment in X-TOLE2 will be completed in late 2024 to early 2025.

XEN1101 for Epilepsy (Primary Generalized Tonic-Clonic Seizures)

The company’s Phase 3 X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures, or PGTCS. This multicenter, randomized, double-blind, placebo-controlled study is evaluating the clinical efficacy, safety, and tolerability of 25 mg of XEN1101 administered with food as adjunctive treatment in approximately 160 patients with PGTCS.

XEN1101 for Epilepsy (Open-Label Extension)

Upon completion of the DBP in X-TOLE2, X-TOLE3, or X-ACKT, eligible patients may enter an open-label extension, or OLE, study for up to three years. In addition, the ongoing X-TOLE Phase 2b OLE, which has been extended from five years to seven years, continues to generate important long-term data for XEN1101.

In November 2023, the company reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 taken once daily with food in 168 patients with moderate to severe major depressive disorder, or MDD.

The company is also collaborating with the Icahn School of Medicine at Mount Sinai to support an ongoing investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled multi-site study of XEN1101 for the treatment of MDD in approximately 60 subjects.

The company has a comprehensive strategy in place to protect and expand the intellectual property portfolio that covers XEN1101. Importantly, two U.S. patents were issued in 2021 with claims covering: distinct crystalline forms of XEN1101 drug substance and related pharmaceutical compositions, along with methods for their preparation and use; and various methods of orally administering XEN1101 with or close to a meal. These U.S. patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term.

In December 2019, the company entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, known as NBI-921352, a clinical stage selective Nav1.6 sodium channel inhibitor, and an exclusive license to pre-clinical compounds for development, including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors. The agreement also included a multi-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors, which was completed in June 2022. Pursuant to the terms of the agreement, the company has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties.

NBI-921352 is being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy, or SCN8A-DEE. A Phase 2 clinical trial is underway evaluating NBI-921352 in pediatric patients (aged between 2 and 21 years) with SCN8A-DEE. Neurocrine Biosciences has received orphan drug and rare pediatric disease designations from the FDA for NBI-921352 in SCN8A-DEE.

In November 2023, Neurocrine Biosciences reported that a Phase 2 clinical trial evaluating NBI-921352 in adult patients with FOS failed to demonstrate meaningful reduction in seizure frequency and that no further development with NBI-921352 in FOS is planned at this time.

Collaborations, Commercial and License Agreements

License and Collaboration Agreement with Neurocrine Biosciences, Inc.

In December 2019, as amended in January 2021 and February 2022, the company entered into a license and collaboration agreement, or the Collaboration Agreement, with Neurocrine Biosciences to establish a collaboration under which the parties will identify, research and develop sodium channel inhibitors, including its clinical candidate XEN901, now known as NBI-921352, and certain preclinical candidates (DTCs) and research compounds which Neurocrine Biosciences will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the Collaboration Agreement.

Neurocrine Biosciences has an exclusive, royalty-bearing, sublicensable license to certain of the company’s intellectual property rights for the research, development and commercialization of these compounds on a worldwide basis for the treatment, cure, diagnosis, prediction or prevention of any human disease or disorder, state, condition and/or malady, subject to certain exceptions set forth in the Collaboration Agreement. The company also granted to Neurocrine Biosciences a non-exclusive, non-royalty-bearing, sublicensable license to certain of its intellectual property rights for the screening of compounds for identification as a Select Nav Inhibitor and for the research of certain compounds otherwise expressly excluded from the Collaboration Agreement, or the Excluded Compounds.

Intellectual Property

As of December 31, 2023, the company owned, co-owned or licensed 16 U.S. issued patents and 56 patents in foreign jurisdictions (exclusive of European patent national validations), and over 370 pending patent applications.

With regard to XEN1101, as of December 31, 2023, the company owned 4 U.S. issued patents, 29 issued patents in foreign jurisdictions (exclusive of European patent national validations) and over 200 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2028 and 2044 (absent any extensions of term).

With regard to NBI-921352 (formerly known as XEN901), as of December 31, 2023, the company owned or co-owned 4 U.S. issued patents, 12 issued patents in foreign jurisdictions (exclusive of European patent national validations), and over 18 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2037 and 2044 (absent any extensions of term). With regard to the company’s selective inhibitors of Nav1.6 and/or Nav1.2 (exclusive of NBI-921352), as of December 31, 2023, it owned 6 U.S. issued patents, 15 issued patents in foreign jurisdictions (exclusive of European patent national validations), and over 90 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2037 and 2039 (absent any extensions of term). Pursuant to its collaboration with Neurocrine Biosciences, Neurocrine Biosciences controls the prosecution, maintenance and other matters relating to the patent portfolio for NBI-921352 and the other selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors, although the company has a right to comment.

With regard to its development programs, including targets related to Kv7 (exclusive of XEN1101), Nav1.1 and Nav1.7, as of December 31, 2023, the company owned 1 U.S. issued patent and over 20 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2036 and 2044 (absent any extensions of term).

Government Regulation

The company is developing small-molecule product candidates, which are regulated as drugs by the FDA and equivalent regulatory authorities outside the U.S. Within the FDA, the Center for Drug Evaluation and Research, or CDER, regulates drugs. Drugs are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and other federal, provincial, state, local and foreign statutes and regulations. The FD&C Act and corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, import, export, reporting, advertising and other promotional practices involving drugs. FDA approval of an investigational new drug application, or IND, must be obtained before clinical testing of drugs is initiated, and each clinical study protocol for such product candidates is reviewed by the FDA and an institutional review board, or IRB, prior to initiation in the U.S. FDA approval also must be obtained before marketing of drugs in the U.S.

The company also must comply with the FDA’s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in or are otherwise inconsistent with the product’s approved labeling (known as off-label use), and industry-sponsored scientific and educational activities. To obtain regulatory approval of an investigational drug under EU regulatory systems, the company must submit a marketing authorization application, or MAA.

History

Xenon Pharmaceuticals Inc. was founded in 1996. The company was incorporated in 1996.

Xenon Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Revenue distribution by industry: Pharmaceutical research and development: 100% (2025) Top 3 markets and their percentage shares: USA: 70% Canada: 15% Europe: 10% Xenon Pharmaceuticals Inc. generates its revenues mainly from pharmaceutical research and development, especially in the field of neu...

At which locations are the company’s products manufactured?

Production Sites: Burnaby, British Columbia, Canada Xenon Pharmaceuticals Inc. is headquartered in Burnaby, British Columbia, Canada, where it also conducts its research and development activities. The company focuses on developing therapies for neurological disorders, leveraging its expertise in ge...

What strategy does Xenon Pharmaceuticals pursue for future growth?

Focus on Pipeline Development: Xenon Pharmaceuticals is strongly focused on the development of its clinical pipeline, especially in the field of neurology. Partnerships and Collaborations: The company relies on strategic partnerships to accelerate research and development and expand market access. E...

Which raw materials are imported and from which countries?

Unfortunately, there are no specific data available on the raw materials and substances that Xenon Pharmaceuticals Inc. imports in 2025. Xenon Pharmaceuticals Inc. is a biopharmaceutical company specializing in drug development. Such companies typically rely on chemical compounds, active ingredients...

How strong is the company’s competitive advantage?

Market Capitalization: $2.5 billion (2025) R&D Expenditure: $150 million (2024) Pipeline Products: 5 in clinical phase (2025) Xenon Pharmaceuticals Inc. has a significant competitive advantage through its specialized research and development in the field of neurology, especially in rare neurol...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: 85% (2025, estimated) Insider Buys/Sells: No significant transactions in the last quarter (2025, estimated) The institutional investor share at Xenon Pharmaceuticals Inc. is relatively high at around 85%, indicating a strong trust from institutional investors in the com...

What percentage market share does Xenon Pharmaceuticals have?

Market share of Xenon Pharmaceuticals Inc.: Estimate: 3% (2025) Top competitors and their market shares: Biogen Inc.: 15% Eli Lilly and Company: 12% Roche Holding AG: 10% Novartis AG: 9% Pfizer Inc.: 8% Amgen Inc.: 7% Sanofi: 6% Merck & Co., Inc.: 5% Bristol-Myers Squibb Company: 4% Xenon Pharm...

Is Xenon Pharmaceuticals stock currently a good investment?

Revenue Growth: 22% (2024) Research and Development Expenses: 35% of revenue (2024) Pipeline Progress: Several Phase III studies ongoing (2025) Xenon Pharmaceuticals Inc. recorded a revenue growth of 22% in 2024, attributed to the successful development and marketing of their products. The company i...

Does Xenon Pharmaceuticals pay a dividend – and how reliable is the payout?

Dividend payment: None (as of 2025) Xenon Pharmaceuticals Inc. currently does not pay any dividends to its shareholders. The company focuses on research and development in the field of neuroscience, particularly on developing new drugs. In the biotechnology industry, it is common for companies in th...

New support ticket

Xenon Pharmaceuticals Stock Value

Xenon Pharmaceuticals Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Xenon Pharmaceuticals do?

Xenon Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal